Fumitremorgin C

Research use only, not for human use.

Fumitremorgin C is a mycotoxin and inhibits ABCG2/BRCP.

Fumitremorgin C is a mycotoxin and inhibits ABCG2/BRCP.(In Vitro):Fumitremorgin C almost completely reverses resistance mediated by BCRP in vitro and is a pharmacological probe for the expression and molecular action of this transporter. Fumitremorgin C enhances the toxicity of mitoxantrone and topotecan in vector-transfected MCF-7 cells (2.5–5.6 fold). It decreases the IC50 of topotecan in BCRP-overexpressing cells below that observed in the untreated vector-transfected cells. Fumitremorgin C is extremely effective in reversing resistance to mitoxantrone, doxorubicin, and topotecan in multidrug-selected cell lines. Fumitremorgin C reverses mitoxantrone resistance (114-fold) and doxorubicin resistance (3-fold), in MCF-7/mtxR. Fumitremorgin C (5/AM) obviously potentiates the toxicity of doxorubicin (26-fold), mitoxantrone (93-fold), and topotecan (24-fold) in S1M1-3.2 cells. Fumitremorgin C does not reverse drug resistance in cells with elevated expression of Pgp or MRP.

——

——

12α-Fumitremorgin C

Membrane Transporter/Ion Channel

BCRP

Estrogen Receptor/ERR| Human Endogenous Metabolite

——

——

118974-02-0

379.46

C22H25N3O3

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (131.77 mM)

[H][C@@]12CCCN1C(=O)[C@]1([H])Cc3c([nH]c4cc(OC)ccc34)[C@]([H])(C=C(C)C)N1C2=O

——

(-20℃)

With Ice Pack

≥ 2 years